Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q) (endTB-Q)

STATUS

Recruiting
End date

Jul 11, 2024
participants needed

324
sponsor

Médecins Sans Frontières, France

Send

Updated on 11 March 2022

See if I qualify

vasectomy

fluoroquinolones

linezolid

pulmonary tuberculosis

bedaquiline

delamanid

clofazimine

bedaquiline 100 mg

linezolid pill

Summary

endTB-Q Clinical Trial is a Phase III, randomized, controlled, open-label, non-inferiority, multi-country trial evaluating the efficacy and safety of two new, all-oral, shortened regimens for multidrug-resistant tuberculosis (MDR-TB) with fluoroquinolone resistance.

Description

This is a Phase III, randomized, controlled, open-label, multi-country trial evaluating the efficacy of new combination regimens for treatment of fluoroquinolone-resistant MDR-TB.

Regimens examined combine newly approved drugs bedaquiline and delamanid with existing drugs known to be active against Mycobacterium tuberculosis (linezolid and clofazimine). The study will enroll in parallel across 1 experimental and 1 standard-of-care control arms, in a 2:1 ratio. Randomization will be stratified by extent-of-TB-disease phenotype. In the experimental arm, treatment will be for 24 or 39 weeks; duration will be assigned according to extent-of-TB-diseasephenotype. In the control arm, treatment will be delivered according to WHO guidelines (and local practice); duration will be variable. Trial participation in both arms will last at least until Week 73, and up to Week 104.

Non-inferiority will be established for the experimental arm if the lower bound of the one-sided 97.5% confidence interval around the difference in favorable outcome between the control and experimental arms is greater than or equal to -12%.

Details

Condition	Tuberculosis, Multidrug-Resistant, Tuberculosis, Pulmonary Tuberculoses, Mycobacterial Infections, Bacterial Infections, Gram-Positive Bacterial Infections
Treatment	Bedaquiline 100 MG, Delamanid 50 MG Oral Tablet, Clofazimine Pill, Linezolid Pill, Control arm MDR-TB regimen, designed according to latest WHO guidelines, Clofazimine 100 MG Oral Capsule, Linezolid 600Mg Tab
Clinical Study Identifier	NCT03896685
Sponsor	Médecins Sans Frontières, France
Last Modified on	11 March 2022

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	Has documented pulmonary tuberculosis due to strains of M. tuberculosis resistant to rifampin (RIF) and not susceptible to fluoroquinolones, according to a validated rapid molecular test
	Is ≥15 years of age
	Is willing to use effective contraception: pre-menopausal women or women whose last menstrual period was within the preceding year, who have not been sterilized must agree to use two methods of contraception (e.g., a hormonal method and a barrier method) unless their partner has had a vasectomy; men who have not had a vasectomy must agree to use condoms
	Provides informed consent for study participation; additionally a legal representative of patients considered minor per local laws should also provide consent
	Lives in a dwelling that can be located by study staff and expects to remain in the area for the duration of the study
Exclusion Criteria
	Has known allergies or hypersensitivity to any of the investigational drugs; 2. Is known to be pregnant or is unwilling or unable to stop breastfeeding an infant; 3. Is unable to comply with treatment or follow-up schedule; 4. Has any condition (social or medical) which, in the opinion of the site principal investigator, would make study participant unsafe; 5. a. Has had exposure (intake of the drug for 30 days or more) in the past five years to bedaquiline, delamanid, linezolid, or clofazimine, or has proven or likely resistance to bedaquiline, delamanid, linezolid, or clofazimine (e.g., household contact of a DR-TB index case who died or experienced treatment failure after treatment containing bedaquiline, delamanid, linezolid, or clofazimine or had resistance to one of the listed drugs); exposure to other anti-TB drugs is not a reason for exclusion
	Has received second-line drugs for 15 days or more prior to screening visit date in the current MDR/RR-TB treatment episode. Exceptions include
	patients whose treatment has failed according to the WHO definition and who are being considered for a new treatment regimen
	patients starting a new treatment regimen after having been "lost to follow-up" according to the WHO definition and
	patients in whom treatment failure is suspected (but not confirmed according to WHO definition), who are being considered for a new treatment regimen, and for whom the Clinical Advisory Committee (CAC) consultation establishes eligibility
	Has one or more of the following
	Hemoglobin ≤7.9 g/dL
	Uncorrectable electrolytes disorders
	Total Calcium <7.0 mg/dL (1.75 mmol/L)
	Potassium <3.0 mEq/L (3.0 mmol/L) or ≥6.0 mEq/L (6.0 mmol/L)
	Magnesium <0.9 mEq/L (0.45 mmol/L)
	Serum creatinine >3 x ULN
	Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) ≥3 x ULN
	Total bilirubin ≥3 x ULN
	Albumin <2.8 g/dL; Unless otherwise specified, Grade 4 result as defined by the MSF Severity Scale on any of the screening laboratory tests. 7. Has cardiac risk factors defined as
	An arithmetic average of the two ECGs with highest QTcF intervals of greater than or equal to 450 ms. Retesting to reassess eligibility will be allowed using an unscheduled visit during the screening phase
	Evidence of ventricular pre-excitation (e.g., Wolff Parkinson White syndrome)
	Electrocardiographic evidence of either
	Complete left bundle branch block or right bundle branch block; OR
	Incomplete left bundle branch block or right bundle branch block and QRS complex duration >120 msec on at least one ECG
	Having a pacemaker implant
	Congestive heart failure
	Evidence of second or third degree heart block
	Bradycardia as defined by sinus rate less than 50 bpm
	Personal or family history of Long QT Syndrome
	Personal history of arrhythmic cardiac disease, with the exception of sinus arrhythmia
	Personal history of syncope (i.e. cardiac syncope not including syncope due to vasovagal or epileptic causes). 8. Is currently taking part in another trial of a medicinal product; 9. Is taking any medication that is contraindicated with the medicines in the trial regimen which cannot be stopped (with or without replacement) or requires a wash-out period longer than 2 weeks

How to participate?

Step 1 Connect with a study center

Select a site
Send a message

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Primary Contact

0/250

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

vasectomy

fluoroquinolones

linezolid

pulmonary tuberculosis

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Edit Delete

Added by •

•

Private

Edit Delete

Reply by • • Private

Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

Enter the passcode

The passcode will expire in None.

Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q) (endTB-Q)